Ga verder naar de inhoud

Phenotyping severe exacerbations of COPD to meet the care needs of patients

CATALINA - A CICERO-initiated, prospective observational cohort study creating a European data & biobank on severe exacerbations to advance COPD research and care

Latest news


Follow our progress

April 3, 2024

ERS/ESC Task Force

September 1, 2023
Original Research

Patient Survey Results

May 31, 2023

Advances in COPD care, the 3rd leading cause of death worldwide,
have been painfully slow over the last 4 decades leaving
millions of patients with a devastating outlook on life.

Paving the way to P4 medicine in COPD

- predictive, preventive, personalized and participatory -

  • CICERO provides a unique network for cross-collaboration
    between all COPD stakeholders to advance research and care.
  • Access to the CATALINA study data- and biobank will provide a deep understanding of risk factors, underlying mechanisms and phenotypes of severe exacerbations to facilitate the development of targeted interventions and prognostication tools.

Interest to contribute and collaborate is highly welcomed !

Cicero icon trees

CRC Structure & Study Members

The CICERO CRC is an European Respiratory Society supported Clinical Research Collaboration between academia, industry, patient representatives and independent international scientific advisors.

The CATALINA study Consortium, embedded within CICERO, is currently comprised of 10 clinical centres from 8 different countries across Europe and their associated expert clinical researchers and young investigators, who drive the momentum for prospective data and sample collection.